Altered α-synuclein, parkin, and synphilin isoform levels in multiple system atrophy brains

Journal of Neurochemistry

Volumn 136, Issue 1, 2016, Pages 172-185

  Brudek, Tomasz ^a,b   Winge, Kristian ^b   Rasmussen, Nadja Bredo ^a   Bahl, Justyna Maria Czarna ^c   Tanassi, Julia ^c   Agander, Tina Klitmøller ^d   Hyde, Thomas M ^e,f   Pakkenberg, Bente ^a  

^a Mental Health Center Glostrup   (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c STATENS SERUM INSTITUT   (Denmark)

^d University of Copenhagen   (Denmark)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

multiple system atrophy; parkin; Parkinson's disease; synphilin; synucleinopathy; synuclein

Indexed keywords

ALPHA SYNUCLEIN; CELL PROTEIN; ISOPROTEIN; PARKIN; SYNPHILIN 1; UNCLASSIFIED DRUG; CARRIER PROTEIN; NERVE PROTEIN; SNCAIP PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ARTICLE; BRAIN LEVEL; CEREBELLUM CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DENTATE NUCLEUS; FEMALE; GENE; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MALE; NERVE DEGENERATION; NEUROTOXICITY; PARK2 GENE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SHY DRAGER SYNDROME; SNCA GENE; SNCA112 GENE; SNCA126 GENE; SNCA140 GENE; SNCA98 GENE; SNCAIP1 GENE; SNCAIP1A GENE; SNCAIP1B GENE; SNCAIP1C GENE; SPLICING DEFECT; SUBSTANTIA NIGRA; TRANSCRIPTION REGULATION; BIOSYNTHESIS; BRAIN; METABOLISM; MIDDLE AGED; PARKINSON DISEASE; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; BRAIN; CARRIER PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PROTEIN ISOFORMS; UBIQUITIN-PROTEIN LIGASES;

EID: 84951906259     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13392     Document Type: Article

References (85)

1. Ahmed Z., Asi Y. T., Sailer A., Lees A. J., Houlden H., Revesz T., and, Holton J. L., (2012) The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol. Appl. Neurobiol. 38, 4-24.
2. Asi Y. T., Simpson J. E., Heath P. R., Wharton S. B., Lees A. J., Revesz T., Houlden H., and, Holton J. L., (2014) Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia 62, 964-970.
3. Beyer K., (2006) Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. 112, 237-251.
4. Beyer K., and, Ariza A., (2007) Protein aggregation mechanisms in synucleinopathies: commonalities and differences. J. Neuropathol. Exp. Neurol. 66, 965-974.
5. Beyer K., and, Ariza A., (2013) Alpha-synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol. Neurobiol. 47, 509-524.
6. Beyer K., Lao J. I., Carrato C., Mate J. L., Lopez D., Ferrer I., and, Ariza A., (2004) Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. Neuropathol. Appl. Neurobiol. 30, 601-607.
7. Beyer K., Humbert J., Ferrer A., Lao J. I., Carrato C., Lopez D., Ferrer I., and, Ariza A., (2006) Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease. NeuroReport 17, 1327-1330.
8. Beyer K., Domingo-Sabat M., Humbert J., Carrato C., Ferrer I., and, Ariza A., (2008a) Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics 9, 163-172.
9. Beyer K., Domingo-Sabat M., Lao J., Carrato C., Ferrer I., and, Ariza A., (2008b) Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics 9, 15-23.
10. Bhidayasiri R., and, Ling H., (2008) Multiple system atrophy. Neurologist 14, 224-237.
11. Bisaglia M., Schievano E., Caporale A., Peggion E., and, Mammi S., (2006) The 11-mer repeats of human alpha-synuclein in vesicle interactions and lipid composition discrimination: a cooperative role. Biopolymers 84, 310-316.
12. Brudek T., Winge K., Agander T. l., and, Pakkenberg B., (2013) Screening of toll-like receptors expression in multiple system atrophy brains. Neurochem. Res. 38, 1252-1259.
13. Bungeroth M., Appenzeller S., Regulin A., Volker W., Lorenzen I., Groetzinger J., Pendziwiat M., and, Kuhlenbaumer G., (2014) Differential aggregation properties of alpha-synuclein isoforms. Neurobiol. Aging 35, 1913-1919.
14. Chung K. K., Zhang Y., Lim K. L., Tanaka Y., Huang H., Gao J., Ross C. A., Dawson V. L., and, Dawson T. M., (2001) Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med. 7, 1144-1150.
15. Cookson M., (2003) Parkins substrates and the pathways leading to neuronal damage. NeuroMol. Med. 3, 1-13.
16. Cykowski M. D., Coon E. A., Powell S. Z., Jenkins S. M., Benarroch E. E., Low P. A., Schmeichel A. M., and, Parisi J. E., (2015) Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain 138, 2293-2309.
17. D'Agata V., and, Cavallaro S., (2004) Parkin transcript variants in rat and human brain. Neurochem. Res. 29, 1715-1724.
18. D'Agata V., Zhao W., and, Cavallaro S., (2000) Cloning and distribution of the rat parkin mRNA. Mol. Brain Res. 75, 345-349.
19. Engelender S., Kaminsky Z., Guo X., et al,. (1999) Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 22, 110-114.
20. Eyal A., Szargel R., Avraham E., Liani E., Haskin J., Rott R., and, Engelender S., (2006) Synphilin-1A: an aggregation-prone isoform of synphilin-1 that causes neuronal death and is present in aggregates from alpha-synucleinopathy patients. Proc. Natl Acad. Sci. 103, 5917-5922.
21. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M. S., Shen J., Takio K., and, Iwatsubo T., (2002) Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160-164.
22. Gilman S., Wenning G. K., Low P. A., et al,. (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670-676.
23. Hattori N., and, Mizuno Y., (1921) Pathogenetic mechanisms of parkin in Parkinson's disease. Lancet 364, 722-724.
24. Henn I. H., Bouman L., Schlehe J. S., et al,. (2007) Parkin mediates neuroprotection through activation of IkB kinase/nuclear factor-kB signaling. J. Neurosci. 27, 1868-1878.
25. Huang Y., Song Y., Murphy K., Holton J., Lashley T., Revesz T., Gai W. P., and, Halliday G., (2008) LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. Acta Neuropathol. 116, 639-646.
26. Humbert J., Beyer K., Carrato C., Mate J. L., Ferrer I., and, Ariza A., (2007) Parkin and synphilin-1 isoform expression changes in Lewy body diseases. Neurobiol. Dis. 26, 681-687.
27. Imai Y., Soda M., and, Takahashi R., (2000) Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275, 35661-35664.
28. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., and, Takahashi R., (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105, 891-902.
29. Ishizawa K., Komori T., Sasaki S., Arai N., Mizutani T., and, Hirose T., (2004) Microglial activation parallels system degeneration in multiple system atrophy. J. Neuropathol. Exp. Neurol. 63, 43-52.
30. Jao C. C., Der-Sarkissian A., Chen J., and, Langen R., (2004) Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc. Natl Acad. Sci. USA 101, 8331-8336.
31. Jellinger K. A., and, Lantos P. L., (2010) Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update. Acta Neuropathol. 119, 657-667.
32. Jin H., Ishikawa K., Tsunemi T., Ishiguro T., Amino T., and, Mizusawa H., (2008) Analyses of copy number and mRNA expression level of the alpha-synuclein gene in multiple system atrophy. J. Med. Dent. Sci. 55, 145-153.
33. Kahle P. J., and, Haass C., (2004) How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep. 5, 681-685.
34. Kahle P. J., Neumann M., Ozmen L., et al,. (2000a) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365-6373.
35. Kahle P. J., Neumann M., Ozmen L., and, Haass C., (2000b) Physiology and pathophysiology of alpha-synuclein: cell culture and transgenic animal models based on a Parkinson's disease-associated protein. Ann. N. Y. Acad. Sci. 920, 33-41.
36. Kahle P. J., Haass C., Kretzschmar H. A., and, Neumann M., (2002) Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. J. Neurochem. 82, 449-457.
37. Kalivendi S. V., Yedlapudi D., Hillard C. J., and, Kalyanaraman B., (2010) Oxidants induce alternative splicing of alpha-synuclein: implications for Parkinson's disease. Free Radic. Biol. Med. 48, 377-383.
38. Kovacs G., Wagner U., Dumont B., et al,. (2012) An antibody with high reactivity for disease-associated alpha-synuclein reveals extensive brain pathology. Acta Neuropathol. 124, 1-14.
39. Lee B. R., and, Kamitani T., (2011) Improved immunodetection of endogenous alpha-synuclein. PLoS ONE 6, e23939.
40. Lee H. J., Choi C., and, Lee S. J., (2002) Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277, 671-678.
41. Lee J. K., Tran T., and, Tansey M., (2009) Neuroinflammation in Parkinsons disease. J. Neuroimmune Pharmacol. 4, 419-429.
42. Li W., West N., Colla E., et al,. (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl Acad. Sci. USA 102, 2162-2167.
43. Low P. A., Reich S. G., Jankovic J., et al,. (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 14, 710-719.
44. Mackenzie I. R., (2000) Activated microglia in dementia with Lewy bodies. Neurology 55, 132-134.
45. Manda K. M., Yedlapudi D., Korukonda S., Bojja S., and, Kalivendi S. V., (2014) The chaperone-like activity of alpha-synuclein attenuates aggregation of its alternatively spliced isoform, 112-synuclein in vitro: plausible cross-talk between isoforms in protein aggregation. PLoS ONE 9, e98657.
46. Marti M. J., Tolosa E., and, Campdelacreu J., (2003) Clinical overview of the synucleinopathies. Mov. Disord. 18, 21-27.
47. McCann H., Stevens C. H., Cartwright H., and, Halliday G. M., (2014) Alpha-synucleinopathy phenotypes. Parkinsonism Relat. Disord. 20 (Supplement 1), S62-S67.
48. McLean P. J., and, Hyman B. T., (2002) An alternatively spliced form of rodent alpha-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in alpha-synuclein aggregation. Neurosci. Lett. 323, 219-223.
49. McLean J. R., Hallett P. J., Cooper O., Stanley M., and, Isacson O., (2012) Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol. Cell Neurosci. 49, 230-239.
50. Miller D. W., Johnson J. M., Solano S. M., Hollingsworth Z. R., Standaert D. G., and, Young A. B., (2005) Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J. Neural. Transm. 112, 1613-1624.
51. Mills J., Kim W., Halliday G., and, Janitz M., (2015) Transcriptome analysis of grey and white matter cortical tissue in multiple system atrophy. Neurogenetics 16, 107-122.
52. Moore D. J., West A. B., Dawson V. L., and, Dawson T. M., (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57-87.
53. Mrak R. E., and, Griffin W. S., (2007) Common inflammatory mechanisms in Lewy body disease and Alzheimer disease. J. Neuropathol. Exp. Neurol. 66, 683-686.
54. Muntane G., Ferrer I., and, Martinez-Vicente M., (2012) Alpha-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 200, 106-119.
55. Murray I. V. J., Giasson B. I., Quinn S. M., Koppaka V., Axelsen P. H., Ischiropoulos H., Trojanowski J. Q., and, Lee V. M. Y., (2003a) Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42, 8530-8540.
56. Murray I., Medford M., Guan H. P., Rueter S., Trojanowski J., and, Lee V., (2003b) Synphilin in normal human brains and in synucleinopathies: studies with new antibodies. Acta Neuropathol. 105, 177-184.
57. Newman A. J., Selkoe D., and, Dettmer U., (2013) A new method for quantitative immunoblotting of endogenous alpha-synuclein. PLoS ONE 8, e81314.
58. Neystat M., Rzhetskaya M., Kholodilov N., and, Burke R. E., (2002) Analysis of synphilin-1 and synuclein interactions by yeast two-hybrid beta-galactosidase liquid assay. Neurosci. Lett. 325, 119-123.
59. Nishie M., Mori F., Fujiwara H., Hasegawa M., Yoshimoto M., Iwatsubo T., Takahashi H., and, Wakabayashi K., (2004) Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol. 107, 292-298.
60. Norris E. H., Giasson B. I., and, Lee V. M. Y., (2004) Alpha-synuclein: normal function and role in neurodegenerative diseases, in Current Topics in Developmental Biology, Stem Cells in Development and Disease (, Gerald P. S., ed), pp. 17-54. Academic Press, London, UK.
61. Okochi M., Walter J., Koyama A., Nakajo S., Baba M., Iwatsubo T., Meijer L., Kahle P. J., and, Haass C., (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 275, 390-397.
62. Ozawa T., Okuizumi K., Ikeuchi T., Wakabayashi K., Takahashi H., and, Tsuji S., (2001) Analysis of the expression level of a-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. Acta Neuropathol. 102, 188-190.
63. Ozawa T., Healy D. G., Abou-Sleiman P. M., et al,. (2006) The alpha-synuclein gene in multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 77, 464-467.
64. Perrin R. J., Payton J. E., Barnett D. H., Wraight C. L., Woods W. S., Ye L., and, George J. M., (2003) Epitope mapping and specificity of the anti-alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines. Neuroscience Letters 349, 133-135.
65. Pfaffl M. W., (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45.
66. Pilsl A., and, Winklhofer K., (2012) Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinsons disease. Acta Neuropathol. 123, 173-188.
67. Polymeropoulos M. H., Lavedan C., Leroy E., et al,. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
68. Reynolds N. P., Soragni A., Rabe M., Verdes D., Liverani E., Handschin S., Riek R., and, Seeger S., (2011) Mechanism of membrane interaction and disruption by alpha-synuclein. J. Am. Chem. Soc. 133, 19366-19375.
69. Salvesen L., Ullerup B. H., Sunay F. B., Brudek T., Lokkegaard A., Agander T. K., Winge K., and, Pakkenberg B., (2015) Changes in total cell numbers of the basal ganglia in patients with multiple system atrophy-a stereological study. Neurobiol. Dis. 74, 104-113.
70. Schmid A. W., Fauvet B., Moniatte M., and, Lashuel H. A., (2013) Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol. Cell Proteomics 12, 3543-3558.
71. Scuderi S., La Cognata V., Drago F., Cavallaro S., and, D'Agata V., (2014) Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain. Biomed. Res. Int. 2014, 690796.
72. Serpell L. C., Berriman J., Jakes R., Goedert M., and, Crowther R. A., (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl Acad. Sci. USA 97, 4897-4902.
73. Shimura H., Hattori N., Kubo S., et al,. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25, 302-305.
74. Shimura H., Schlossmacher M. G., Hattori N., Frosch M. P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K. S., and, Selkoe D. J., (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263-269.
75. Sriram S. R., Li X., Ko H. S., Chung K. K. K., Wong E., Lim K. L., Dawson V. L., and, Dawson T. M., (2005) Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum. Mol. Genet. 14, 2571-2586.
76. Stefanova N., Bucke P., Duerr S., and, Wenning G. K., (2009) Multiple system atrophy: an update. Lancet Neurol. 8, 1172-1178.
77. Stichel C. C., Augustin M., Kuhn K., Zhu X. R., Engels P., Ullmer C., and, Lubbert H., (2000) Parkin expression in the adult mouse brain. Eur. J. Neurosci. 12, 4181-4194.
78. Sunada Y., Saito F., Matsumura K., and, Shimizu T., (1998) Differential expression of the parkin gene in the human brain and peripheral leukocytes. Neurosci. Lett. 254, 180-182.
79. Tan J. M., Wong E. S., and, Lim K. L., (2009) Protein misfolding and aggregation in Parkinson's disease. Antioxid. Redox Signal. 11, 2119-2134.
80. Trojanowski J. Q., Revesz T., and the Neuropathology Working Group on MSA (2007) Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol. Appl. Neurobiol. 33, 615-620.
81. Wakabayashi K., Engelender S., Tanaka Y., Yoshimoto M., Mori F., Tsuji S., Ross C., and, Takahashi H., (2002) Immunocytochemical localization of synphilin-1, an a-synuclein-associated protein, in neurodegenerative disorders. Acta Neuropathol. 103, 209-214.
82. Wenning G. K., Colosimo C., Geser F., and, Poewe W., (2004) Multiple system atrophy. Lancet Neurol. 3, 93-103.
83. Wenning G. K., Geser F., Krismer F., et al,. (2013) The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 12, 264-274.
84. Yoshimoto M., Iwai A., Kang D., Otero D. A., Xia Y., and, Saitoh T., (1995) NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc. Natl Acad. Sci. 92, 9141-9145.
85. Zhang Y., Gao J., Chung K. K., Huang H., Dawson V. L., and, Dawson T. M., (2000) Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl Acad. Sci. USA 97, 13354-13359.